RSV Vaccine Performance in U.S. Adults Aged 60 and Older

During the 2023–2024 respiratory syncytial virus season, effectiveness of RSV vaccines in older adults was 77% against RSV-related ED visits and 80% against hospitalization.

In June 2023, the protein-based respiratory syncytial virus (RSV) vaccines Abrysvo and Arexvy were recommended in the U.S. to persons aged ≥60 years; however, trials supporting licensure were not powered for the clinically relevant endpoints of RSV-related hospitalization and emergency department (ED) visits. In an electronic medical records–based study encompassing nine healthcare systems in eight states, investigators used a test-negative design to assess the effectiveness of RSV vaccines against RSV-related hospitalization and ED visits in persons aged ≥60 from October 2023 through March 2024 (the first RSV season after vaccine approval).

In all, 36,706 hospitalizations (94% with ≥1 comorbidity) and 37,842 ED visits (48% with ≥1 comorbidi…

Reviewing Author

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

RSV Vaccine Performance in U.S. Adults Aged 60 and Older

Topics

Reviewing Author